Qualigen Therapeutics Inc (QLGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qualigen Therapeutics Inc (QLGN) has a cash flow conversion efficiency ratio of -0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.14 Million) by net assets ($38.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Qualigen Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Qualigen Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Qualigen Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Qualigen Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qualigen Therapeutics Inc ranked by their cash flow conversion efficiency. Explore QLGN cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MRG Metals Ltd
AU:MRQ
|
-0.043x |
|
Helios Energy Ltd
AU:HE8
|
-0.020x |
|
Kia Lim Bhd
KLSE:6211
|
0.024x |
|
H3 Energy Limited
AU:H3E
|
0.355x |
|
Eminence Minerals Limited
AU:EMA
|
-0.112x |
|
Foresight Solar Fund Ltd
LSE:FSFL
|
0.015x |
|
CN Asia Corporation Bhd
KLSE:7986
|
0.017x |
|
PayPoint plc
LSE:PAY
|
0.845x |
Annual Cash Flow Conversion Efficiency for Qualigen Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Qualigen Therapeutics Inc from 2012 to 2024. View Qualigen Therapeutics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.68 Million | $-6.33 Million | -2.362x | -148.22% |
| 2023-12-31 | $-2.10 Million | $-10.30 Million | 4.898x | +424.16% |
| 2022-12-31 | $8.77 Million | $-13.25 Million | -1.511x | -69.93% |
| 2021-12-31 | $16.56 Million | $-14.73 Million | -0.889x | -66.77% |
| 2020-12-31 | $18.29 Million | $-9.76 Million | -0.533x | -1123.08% |
| 2019-12-31 | $1.10 Million | $57.33K | 0.052x | +103.67% |
| 2018-12-31 | $9.39 Million | $-13.33 Million | -1.420x | -286.43% |
| 2017-12-31 | $20.13 Million | $-7.40 Million | -0.368x | +90.08% |
| 2016-12-31 | $4.10 Million | $-15.21 Million | -3.707x | -851.36% |
| 2015-12-31 | $14.68 Million | $-5.72 Million | -0.390x | +42.48% |
| 2014-12-31 | $1.71 Million | $-1.16 Million | -0.677x | -112.12% |
| 2013-12-31 | $-350.25K | $-1.96 Million | 5.587x | +271.69% |
| 2012-12-31 | $946.03K | $-3.08 Million | -3.254x | -- |
About Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS tha… Read more